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ABSTRACT
Serotype 19F pneumococci were a leading cause
of infections among children in Athens, Greece
during 2001–2006. In total, 143 19F isolates were
typed by pulsed-ﬁeld gel electrophoresis (PFGE),
and 38 isolates representing the main PFGE types
were also characterised by multilocus sequence
typing. A diversity of distinct strains belonging to
sequence types 236, 1035, 274, 172 and 319 were
identiﬁed, but multidrug-resistant isolates related
to the Taiwan19F-14 clone (ST236) constituted
76.9% of the isolates. Spread of the Taiwan19F-14
clone explains, in part, the high incidence of
antibiotic resistance observed among pneumococ-
ci reported recently from Athens.
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Treatment of pneumococcal infections can be
complex because of the dissemination of clones
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exhibiting resistance to various antibiotics,
including penicillin and macrolides [1,2]. High
isolation rates of multidrug-resistant pneumo-
cocci from children in Greece have been reported.
These isolates were commonly recovered from
non-invasive pneumococcal disease, mainly acute
otitis media, but also from healthy carriers, and
often belonged to serotype 19F [3–5]. The present
study investigated 143 pneumococci of sero-
type 19F isolated between January 2001 and April
2006 from children (aged £14 years) in Athens
(Table 1). In the pre-vaccination period (2001–
2004), serotype 19F isolates constituted a signiﬁ-
cant proportion (31.8%) of pneumococci isolated
in the main paediatric hospitals of Athens (Aghia
Soﬁa, A. & P. Kyriakou and Penteli Hospitals).
The characteristics of the pre-vaccination isolates
have been described previously [5]. Seventy-
seven of the 328 serotype 19F isolates from this
collection were available for inclusion in the
present study (Table 1). Between 2005 and April
2006, 169 isolates were recovered from cases of
invasive pneumococcal disease and non-invasive
pneumococcal disease among children attending
a post-vaccination sentinel hospital in Athens
(Aghia Soﬁa) for the follow-up of pneumococcal
infections. Of these, 58 (34.3%) isolates belonged
to serotype 19F, and this serotype was also
common (18.5%) among 189 isolates derived
from healthy carriers during the post-vaccination
period. Sixty-six isolates of serotype 19F (42 from
infections and 24 from carriers) had been retained
in the hospital laboratory and were included in
the study (Table 1). An additional isolate
(UK-GR), representing an erythromycin-resistant
19F clone isolated in 1996 [6], was also included
for comparison.
Serotypes were determined using the Quellung
reaction with pooled and selected factor antisera
(Statens Seruminstitut, Copenhagen, Denmark).
Penicillin, amoxycillin, cefotaxime and oﬂoxacin
MICs were determined by Etests (AB Biodisk,
Solna, Sweden). Susceptibility to erythromycin,
clindamycin, co-trimoxazole, tetracycline,
chloramphenicol and rifampicin was assessed by
disk-diffusion, interpreted as recommended by the
CLSI [7]. Phenotypic characterisation of macrolide
resistance was also performed [8].
Pneumococci were typed by pulsed-ﬁeld gel
electrophoresis (PFGE), with preparation of geno-
mic DNA and electrophoresis conditions as
described previously [6]. Isolates with PFGE
patterns differing by one to six bands were
assigned to different subtypes within the same
type [9]. Isolates representing the main PFGE
types and subtypes were also characterised by
multilocus sequence typing (MLST), based on
sequence analysis of seven housekeeping genes,
i.e., aroE, gdh, gki, recP, spi, xpt and ddl [10].
Sequences were determined on both DNA
strands, and were compared with those available
at the MLST website (http://www.mlst.net).
Novel alleles and new sequence types (STs) were
assigned new numbers and deposited in the
Streptococcus pneumoniae MLST database. Clonal
complexes (CCs) were deﬁned using EBURST
software.
PFGE typing of 143 pneumococci belonging to
serotype 19F revealed 18 types, further divided
into a total of 55 subtypes. Ten types were
represented by one isolate each, while two or
more isolates clustered in the remaining eight
types, labelled A (six isolates; ﬁve subtypes), B
(two; two), C (two; two), D (three; two), E (two;
two), F (six; four), G (110 isolates, 55 of which
belonged to only one of the 30 subtypes), and H
(two; two) (Table 2). The 19F erythromycin-resis-
tant clone described previously (UK-GR), derived
from children in Athens in 1996 [6], also belonged
to type G, but represented a distinct subtype not
observed among the current isolates.
Thirty-six isolates belonging to seven PFGE
types (A, C, D, E, F, G and H) and two isolates
exhibiting unique PFGE patterns were further
typed by MLST. Thirteen STs, distributed into
seven CCs, were identiﬁed (Table 2). Five allelic
proﬁles had not been observed previously and
were assigned new ST numbers. PFGE type G
isolates were either ST236 (15-16-19-15-6-20-26)
(n = 25, including the UK-GR isolate from 1996),
corresponding to the Taiwan19F-14 clone, or were
novel single-locus variants of ST236: ST 2320
(15-16-19-15-6-193-26); ST 2321 (15-16-19-15-6-20-
Table 1. Pneumococcal isolates from Athens, Greece,
showing the source of the serotype 19F isolates included
in the study
Source
2001–2004 2005 to April 2006
Total 19F (%) Studied Total 19F (%) Studied
IPD 186 12 (6.5) 8 36 7 (19.4) 7
NIPD 641 279 (43.5) 53 133 51 (38.3) 35
Carriage 206 37 (18.0) 16 189 35 (18.5) 24
Total 1033 328 (31.8) 77 358 93 (26.0) 66
IPD, invasive pneumococcal disease; NIPD, non-invasive pneumococcal disease.
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226); ST 2322 (15-16-19-15-6-20-228); and ST 2323
(7-16-19-15-6-20-26). The latter ST is probably
derived from an ST236 strain by recombination
in the aroE locus. Thus, typing indicated that the
majority of the multidrug-resistant serotype 19F
pneumococci were indistinguishable from, or
closely related to, the international clone Tai-
wan19F-14 (CC271). Both isolates of PFGE group F
belonged to ST177, corresponding to the Portu-
gal19F-21 clone (CC177). Isolates of PFGE types A,
C, D, E and H were ST1035 (CC162), ST274
(CC199), ST172 (CC172), ST319 (CC230) and
ST344 (CC344), respectively. Two isolates with
unique PFGE patterns were ST416 (CC199) and
ST2324 (a novel single-locus variant of ST177).
All Taiwan19F-14-related isolates were multi-
drug-resistant (i.e., resistant to three or more drug
classes), compared with only 15 (45.5%) of the
remaining 33 pneumococci belonging to all other
types (Table 2). All were penicillin-non-suscepti-
ble, exhibiting either intermediate (MICs 0.064–
1 mg ⁄L) (43.6%) or high-level (MICs ‡2 mg ⁄L)
(56.4%) resistance. Thirteen (11.8%) of the peni-
cillin-non-susceptible type G isolates were also
non-susceptible to cefotaxime (MICs 2–8 mg ⁄L).
Isolates of this cluster were all resistant to eryth-
romycin, but only 4.5% were resistant to clinda-
mycin. The M phenotype, i.e., resistance to
erythromycin and susceptibility to clindamycin,
thus predominated (95.5% of the 110 Taiwan19F-
14-related isolates), which is consistent with
previous reports suggesting an association of this
clone with mef genes [11,12]. Rates of resistance to
co-trimoxazole and tetracycline among these
isolates were 89.1% and 92.7%, respectively. All
143 isolates were susceptible to amoxycillin,
chloramphenicol, oﬂoxacin and rifampicin.
The Taiwan19F-14 clone is disseminated mostly
in Asian countries, South Africa and the USA
[11–14], and is isolated only infrequently in
Europe [15–17]. The present study provides
evidence of the persistence and spread of isolates
of this clone among children in Greece, thereby
accounting, to a large extent, for the high resis-
tance rates observed recently among pneumococci
in Greece [4,5]. Taiwan19F-14-related isolates have
circulated in this community since at least 1996, as
indicated by typing of the UK-GR clone. Another
ST236 strain (JJ271-19F), isolated in Greece during
1997, has been found in the MLST database,
thereby providing further evidence that this ST
was present before the study period, but the
signiﬁcance of this clone during the 1990s cannot
be reliably assessed. These ﬁndings also highlight
the differences among communities in the distri-
bution of pneumococci. Indeed, in neighbouring
countries, isolates related to this clone remain
uncommon [18–20].
Over 75% of the Taiwan19F-14-related pneu-
mococci belonged to the same PFGE type, G.
However, differences in both phenotypes and
DNA ﬁngerprints, as well as the emergence of
novel STs among type G isolates, suggest an
actively evolving clone. The frequent isolation of
Taiwan19F-14-related pneumococci among carri-
ers, and their over-representation among cases of
acute otitis media, probably reﬂect the high
colonisation potential of this serotype. Although
it is still premature to evaluate the impact of the
seven-valent conjugate vaccine, these ﬁndings are
in line with previous observations suggesting that
19F is the least affected of the vaccine serotypes
[21]. In addition, the high population density in
Athens and the extensive use of macrolides
Table 2. Characteristics of 143 Streptococcus pneumoniae isolates belonging to serotype 19F
PFGE type (n) Isolation period Clinical source (n) Resistance phenotype (n) ST CC
A (6) 2001–2003, 2006 IPD (2), NIPD (2), carriage (2) Susceptible (3), PenErySxtTet (2)
PenErySxtTetCli (1)
1035 162
B (2) 2005 IPD (1), carriage (1) Susceptible (2) ND
C (2) 2004, 2005 NIPD (2) Susceptible (2) 274 199
D (3) 2002, 2004 IPD (1), NIPD (2) Susceptible (3) 172 172
E (2) 2001–2006 NIPD (1), carriage (1) Susceptible (1), PenErySxtTetCli (1) 319 230
F (6) 2002–2005 NIPD (5), carriage (1) Susceptible (3), PenErySxtTet (1),
PenErySxtTetCli (1), PenEryTet (1)
177 177
G (110) 2001–2006 IPD (11), NIPD (67),
carriage (32)
PenErySxtTet (75), PenEryTet (12),
PenCtxErySxtTet (10), PenErySxt (8),
PenCtxErySxtTetCli (3), PenErySxtTetCli (2)
236, 2320, 2321,
2322, 2323
271
H (2) 2004, 2006 Carriage (2) Susceptible (1), ErySxtTet (1) 344 344
Unique types (10) 2001–2006 NIPD (9), carriage (1) Susceptible (3), PenErySxtTet (6), ErySxtTet (1) 416,
2324
199,
177
PFGE, pulsed-ﬁeld gel electrophoresis; Pen, penicillin; Ctx, cefotaxime; Ery, erythromycin; Sxt, co-trimoxazole; Tet, tetracycline; Cli, clindamycin; ND, not determined; IPD,
invasive pneumococcal disease; NIPD, non-invasive pneumococcal disease; ST, sequence type; CC, clonal complex.
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(among the highest in Europe) [22] have probably
facilitated transmission and establishment of this
clone. The low frequency of isolation of the less
resistant 19F isolates that are unrelated to the
Taiwan19F-14 clone supports the important role of
selection pressure in this setting.
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